XORTX Therapeutics Inc is a clinical-stage pharmaceutical company focused on developing therapies to treat gout and progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications such as allopurinol-intolerant gout and autosomal dominant polycystic kidney disease, as well as more prevalent type 2 diabetic nephropathy and fatty liver disease. Its focus is on developing products to slow and/or reverse the progression of these diseases. The Company operates in one reportable operating segment: the development and commercialization of therapies to treat hyperuricemia-related diseases.
Last trade$0.9801
Day change-$0.0599 (-5.76%)
Day range$0.9208 – $1.03
Volume45,101
Market cap$2M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
No ratio data was found for XRTX.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
No quarterly
income statement data was found for XRTX.
Recent news
Company coverage with links to the original publishers.
XORTX Therapeutics announced that the Japan Patent Office has issued a Decision to Grant a patent for its xanthine oxidase inhibitor compositions (XRx-101) for treating acute kidney injury and other health consequences of viral infections. The patent, expected to remain in force until March 2041, marks the company's first patent protection in Japan and strengthens its intellectual property position in one of the world's largest pharmaceutical markets.
XORTX Therapeutics has terminated its US$2.5 million investor relations and marketing agreement with IR Agency LLC effective August 7, 2026, with all funds returned to the company. The decision was made to postpone the IR program during the company's voluntary delisting from the TSX Venture Exchange, expected to take effect September 1, 2026. The company aims to reduce regulatory complexity and focus resources on clinical development. Additionally, XORTX disclosed previously omitted finder's fees of US$240,000 related to its April 2026 acquisition of Vectus Biosystems' Renal Anti-Fibrotic Therapeutic Program.
XORTX Therapeutics Inc. has elected to voluntarily delist its common shares from the TSX Venture Exchange (TSXV) to reduce costs and administrative burden. The company will maintain its listings on Nasdaq and Frankfurt. The delisting is expected to eliminate duplicative exchange fees, reduce legal and accounting expenses, and allow management to focus on advancing its XRx-026 gout treatment program. Canadian shareholders will retain full trading access on Nasdaq.
XORTX Therapeutics has completed its acquisition of the VB4-P5 program from Vectus Biosystems, a novel therapeutic targeting kidney fibrosis in chronic kidney disease. The deal valued at US$3.0 million includes patent rights and preclinical data. VB4-P5 is positioned to address a significant unmet medical need in both rare and prevalent kidney diseases affecting millions globally.
XORTX Therapeutics announced that its 1-for-5 share consolidation has received all required approvals from TSX Venture Exchange and Nasdaq Stock Exchange, effective April 6, 2026. The company is a late-stage clinical pharmaceutical firm developing therapies for gout and progressive kidney disease, with three clinically advanced products in development.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.